Sequent Scientific Limited has informed the Exchange about Investor Presentation
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sequent Scientific reported strong Q4 FY25 results with revenue of ₹4,017 million (up 11.2% YoY) and EBITDA of ₹569 million (up 38.7%). For the full year FY25, revenue grew 13.3% to ₹15,514 million while EBITDA jumped 86.6% to ₹1,993 million, with EBITDA margins expanding sharply by 500 basis points to 12.8%. Net debt-to-EBITDA improved significantly from 3.5x to 1.9x. The proposed merger with Viyash Life Sciences is on track — CCI approval has been received and stock exchange NOC is awaited before NCLT filing, with expected completion in 12-15 months. On a combined proforma basis, FY25 revenue stood at ₹30,094 million with adjusted EBITDA margin of 15.1%. Management highlighted four core synergy areas (R&D, Manufacturing, Sales, and shared services) and growth pillars spanning API++, Global Formulations, and Strategic Innovator/CDMO segments.
Positive for shareholders — strong margin expansion, major deleveraging, and a value-accretive merger progressing on schedule. The presentation signals sustained earnings momentum and a credible path to scale, which should support the stock's outlook.